Kotyark Industries' record shows five years of unqualified audit opinions and a business that has scaled from zero subsidiaries to five in four years. Three things deserve attention: cumulative operating cash flow covers only 31% of profit over four years, the company is seeking approval to borrow up to ₹750 crore against current debt of ₹78 crore, and a criminal proceeding against a director remains unresolved alongside seized inventory still carried on the books.
Key findings
- Operating cash flow covers only 31% of cumulative profit, with FY26 deeply negative
Major- Cumulative CFO of ₹21 crore covers only 0.31 times cumulative PAT of ₹70 crore (net of other income) over FY23-FY26, with FY26 CFO at negative ₹3.92 crore against PAT of ₹19.36 crore. The Board paid an interim dividend of ₹7.50 per share in October 2024 and recommended a final dividend of ₹5.00, while net proceeds from borrowings were ₹19.00 crore in FY26. Management stated in the Q4 FY26 call that new facilities are "being funded through internal accruals," despite the negative CFO and increased borrowings. - The company seeks approval to borrow up to ₹750 crore, approximately 9.7 times current standalone debt
Major- The Board is seeking a special resolution to permit total outstanding borrowings up to ₹750 crore, as stated in the FY2025-26 AGM notice. Standalone borrowings stood at ₹77.73 crore, making the proposed limit approximately 9.7 times current debt. [SQL] Subsidiary Kotyark Bio Specialities Limited issued three series of unsecured Compulsory Convertible Debentures totalling over ₹19 crore, classified as equity under Ind AS in the consolidated statements rather than as borrowings. - Promoter family dominates the board, with remuneration up 70% and 122% while promoters sold over 10 percentage points of their stake
Major- Chairman-cum-MD Gaurang R. Shah, Whole-Time Director & CFO Dhruti M. Shah, and Non-Executive Director Bhaviniben G. Shah are all members of the promoter family. Gaurang R. Shah's remuneration was revised to up to ₹17 lakh per month effective September 1, 2024, a 70% increase, while Dhruti M. Shah's rose 122% to up to ₹4 lakh per month. Promoter shareholding fell from 67.66% to 57.34% during FY2025-26, driven by open-market sales by promoter entities. - Audit opinions are unqualified, but quarterly bank-return mismatches recur every year and FY26 introduces an Emphasis of Matter on seized inventory and criminal proceedings
Major- The standalone and consolidated audit opinions were unqualified in every year from FY2020-21 through FY2025-26. However, CARO clause ii(b) reports differences in inventory and trade receivables versus books in every year from FY2021-22 through FY2025-26. The FY2025-26 audit report includes an Emphasis of Matter: authorities seized four storage tanks of raw material at the Swaroopganj unit and initiated criminal proceedings against one director. - A criminal proceeding against a director and seizure of raw material remain unresolved, while bio-fuel registration renewal has been pending since July 2022
Major- The Bio-Fuel Authority registration for the Swaroopganj unit expired on July 31, 2022, and renewal had not been granted as of the FY2025-26 annual report date. On July 2, 2025, authorities seized four storage tanks containing 6,84,000 litres of raw material and initiated criminal proceedings against one director; the Rajasthan High Court stayed the criminal proceeding on August 6, 2025, and permitted continuation of operations on August 26, 2025. The value of the seized raw material continues to be carried as inventory. - RPT approval limits have escalated from ₹200 crore to ₹500 crore in four years while actual transactions remain a fraction of limits
Minor- Shareholder approval limits for loans, guarantees, and investments to group entities rose from ₹200 crore in FY2023-24 to ₹500 crore in FY2026-27. The aggregate RPT approval limit for subsidiary Kotyark Bio Specialities Limited increased from ₹150 crore to ₹250 crore, representing 484% of that subsidiary's standalone turnover. Actual transactions with that subsidiary in FY2025-26 totalled ₹36.61 crore against the approved limit of ₹150 crore. - The group expanded from zero subsidiaries in FY21 to five by FY26, with two LLPs ceasing to be subsidiaries within three months of incorporation
Minor- The group had no subsidiaries in FY2020-21 and expanded to five by March 31, 2026. Two subsidiary LLPs incorporated in December 2025 ceased to be subsidiaries effective April 1, 2026, after the parent ceased to be a Partner and Designated Partner. Subsidiary Kotyark Bio Specialities Limited issued three series of unsecured CCDs totalling over ₹19 crore, convertible into equity shares over up to 10 years, which will dilute the parent's holding upon conversion.
What to watch
- Borrowing-authorisation vote. Outcome of the August 2, 2026 AGM vote on the special resolution to authorise borrowings up to ₹750 crore.
- RPT and loan-limit votes. Outcome of shareholder votes on material RPTs with Kotyark Bio Specialities Limited up to ₹250 crore, and Section 185 and 186 approvals for loans and guarantees up to ₹250 crore and ₹500 crore, at the AGM on August 2, 2026.
- Criminal proceedings and seized inventory. Resolution of the criminal proceedings against one director and release of the seized raw material at the Swaroopganj unit, pending as of the audit report dated April 27, 2026.
- Bio-Fuel Authority registration. Renewal of the company's registration with the Bio-Fuel Authority, Government of Rajasthan, pending as of the audit report dated April 27, 2026.
Bottom line: This is a disclosed and audited record with a real operating business that has scaled rapidly. The risk sits in three places: cash conversion that lags reported profit by a wide margin, a borrowing-authorisation vote that would multiply the debt ceiling by eleven times, and an unresolved regulatory action that leaves seized inventory on the books. Watch the AGM votes on August 2, 2026, and whether the bio-fuel registration and criminal proceedings reach resolution.